FDA Requested More Survival Data for Tovecimig
The FDA wants further evidence of survival benefits before considering approval for this biliary tract cancer drug.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Should regulators expedite drug approvals even if long-term survival data is currently incomplete?
The FDA has advised Compass Therapeutics to conduct an additional clinical trial demonstrating a survival benefit before submitting a Biologics License Application for the investigational cancer drug tovecimig. The company maintains that existing trial data for the biliary tract cancer treatment is sufficient for submission.
Why it matters
This regulatory decision impacts the development timeline for a potential new therapy for biliary tract cancer, an area with significant unmet medical needs. The move highlights the agency's requirement for robust survival metrics before allowing market access for novel bispecific antibodies.
Results from the Phase 2/3 COMPANION-002 study showed an objective response rate of 18.0% for the tovecimig and paclitaxel combination compared to 5.3% for paclitaxel alone. The median progression-free survival was 4.7 months for the treatment group versus 2.6 months for the control.
The players
Compass Therapeutics
A Boston-based biotechnology company focused on the development of bispecific antibodies and therapies for oncology.
FDA
The United States government agency responsible for the regulation and safety of medical products and drugs.
The details
Tovecimig is a bispecific antibody designed to block two angiogenic pathways, DLL4 and VEGF-A, simultaneously. By targeting these dual pathways, the investigational therapy aims to disrupt the blood supply that fuels tumor growth. Compass Therapeutics intends to continue engaging with federal regulators to determine how to proceed with their BLA submission plans.
Timeline
September 22, 2026: Compass Therapeutics announced the regulatory feedback from the FDA.
Health Landscape
This development highlights the evolving regulatory standard for accepting mid-stage clinical data in oncology. The agency's request marks a point where the demand for definitive survival endpoints persists despite the urgency of fast-track designations for rare cancers.
Patients with biliary tract cancer should remain aware that tovecimig is currently an investigational drug and not yet available for treatment. Specific questions regarding the availability of clinical trials or alternative treatment options are best discussed with your oncologist.
The takeaway
The FDA's guidance underscores that objective response rates and progression-free survival metrics are often insufficient to establish the clear survival benefit required for drug approval. Patients following developments in rare cancer treatments should discuss new clinical trial findings with their physician.
Further reading
For context on the current research landscape for rare malignancies, visit the Cancer section.
Live Poll
Should regulators expedite drug approvals even if long-term survival data is currently incomplete?
